Daniel Schoenborn, DO
Gastroenterology · Columbus, GANPI 1326252503
Payments from drug & device makers
Across 340 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$940
- Pfizer$509
- Bristol Myers Squibb$391
- Sanofi$355
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$342
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,69798%
- Education$851%
- Gifts$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $1,612 |
| Johnson & Johnson(2 entities) | 51 | $940 |
| Pfizer | 33 | $509 |
| Bristol Myers Squibb | 27 | $391 |
| Sanofi | 15 | $355 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $342 |
| Gilead | 13 | $239 |
| Intercept Pharmaceuticals, Inc. | 12 | $212 |
| Regeneron Healthcare Solutions, Inc. | 8 | $203 |
| Evoke Pharma, Inc. | 9 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $164 |
| Ardelyx, Inc. | 7 | $141 |
| Ironwood Pharmaceuticals, Inc | 5 | $108 |
| Enterra Medical, Inc. | 1 | $63 |
| Phathom Pharmaceuticals, Inc. | 4 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Merck | 2 | $44 |
| Boston Scientific | 2 | $43 |
| Lilly USA, LLC | 2 | $35 |
| Shire North American Group Inc | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $19 |
| Intra-sana Laboratories | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Madrigal Pharmaceuticals | 1 | $13 |
How this compares
$5,796 in reported general payments places this provider in the 60th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 27 | $255,055 |
| Dupixent PenDupilumab | 14 | $97,758 |
| CreonLipase/Protease/Amylase | 22 | $64,931 |
| LinzessLinaclotide | 42 | $36,265 |
| TrulancePlecanatide | 14 | $16,194 |
| Ursodiol | 31 | $9,958 |
| Pantoprazole Sodium | 448 | $7,178 |
| Colesevelam Hcl | 55 | $7,125 |
| Dexlansoprazole DrDexlansoprazole | 14 | $5,596 |
| Dicyclomine Hcl | 204 | $5,566 |
| Lubiprostone | 25 | $3,741 |
| Azathioprine | 16 | $2,921 |
| Esomeprazole Magnesium | 49 | $2,399 |
| Budesonide DrBudesonide | 27 | $2,385 |
| Rabeprazole Sodium | 47 | $2,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $212 | $255,05527 claims |
| AbbVieCreon, Linzess | $1,612 | $101,19664 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $342 | $16,19414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Columbus
- Shankar ThiruppathiColumbus$265K
- Michael SteinbookColumbus$155K
- Pravinchandra PatelColumbus$97K
- Ashwin PatelColumbus$56K
- Douglas WolfAtlanta$6.4M
- Aasim SheikhMarietta$6M
- Shahriar SedghiMacon$5.4M
- Jeffrey WilliamsAthens$2.5M
- Michael GalambosAtlanta$1.8M
- Nitin GuptaAtlanta$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.